Life Sciences Webcast Series

Kroll is excited to announce that Michael Kiely, President of U.S. Government Affairs at UPS and Jon Selib, Senior Vice President, Global Policy & Public Affairs at Pfizer will join Kroll's Chief Strategist Chris Campbell for a webcast to discuss the role of regulation in the life sciences industry. We hope you will join us!

Key Discussion Topics

• Will regulators be globally aligned?
• ESG Regulation under the Biden Administration.
• Is there potential for industry and regulators to work closely in sharing ‘real-time’ data?
• Critical emerging trends and hot topics.

Date and Time

Thursday, June 24, 2021

11:00 a.m. EDT/4:00 p.m. BST

This exciting event is part of a series of webinars, bringing together top experts and industry leaders to set the roadmap for a new era where pharma, patients, providers and society are united in their efforts of greater value. Please join us for our virtual Life Sciences Series held on June 22-24, 2021. Together, our leading experts and industry leaders will share insights on trends, valuation, technology, intellectual property (IP), risk and regulation to set the roadmap for a new era where pharma, patients, providers and society are united in their efforts of greater value.

Guest Speakers

• Jon Selib, Senior Vice President, Global Policy & Public Affairs at Pfizer
• Michael Kiely, President of U.S. Government Affairs at UPS
• Dr. Penny Gilbert, Partner, Powell Gilbert LLP
• John Ingrassia, Senior Counsel, Proskauer Rose LLP
• Barbara Fiacco, Partner, Foley Hoag
• PJ McCarthy, Partner, Goodwin
• Roeland Van Aelst, EMEA Lead Third Party Intermediary Ethics & Compliance, Johnson & Johnson
• James D’Arecca, Chief Financial Officer, TherapeuticsMD
• Jan Bregman, Senior Manager, AtaCor Medical, Inc

Agenda

Day 1: Tuesday, June 22

Key Insights and Trends

Schedule: 11:00 a.m. EST / 4:00 p.m. BST

As big pharma and biotech conglomerates continue to seek growth following the COVID-19 pandemic, we will be joined by experts from within Duff & Phelps, A Kroll Business and the wider industry to who will look ahead to what will shape the future of the life sciences industry and dissect the key drivers of M&A activity.

Key Insights

• Deal trends and investment opportunities
• Digitalization and remote engagement in healthcare
• The importance of environmental, social, and corporate governance (ESG)

Panelists

• Andreas Chrysostomou, Managing Director, Duff & Phelps
• Brooks Dexter, Managing Director, Duff & Phelps
• Andrew Probert, Managing Director, Duff & Phelps
• James D’Arecca, Chief Financial Officer, TherapeuticsMD

Biotechnology Purchase Accounting Valuation

Schedule: 12:15 p.m. EST / 5:15 p.m. BST

Purchase accounting valuation in the biotechnology industry can be particularly challenging.  Understanding the intricacies of biotechnology valuation and having command of best practices is key to successfully navigating the valuation process for all stakeholders.  Duff & Phelps’ Life Sciences valuation advisory team will hold a webinar where we will walk you through a purchase price allocation for a hypothetical biotechnology company based on real-world experience.

Key Insights

• Key considerations and intricacies regarding unit of account decisions in product/product candidate valuation.
• Unique inventory valuation considerations in biotechnology acquisitions
• Valuation of biotechnology collaborations/licensing arrangements
• Contingent liability and contingent consideration valuation
• Navigating the audit process and documentation

Panelists

• Andreas Chrysostomou, Managing Director, Duff & Phelps
• Jonathan Goldblatt, Managing Director, Duff & Phelps
• Frank Deluccia, Director, Duff & Phelps
• David Nadell, Director, Duff & Phelps

Day 2: Wednesday, June 23

The Impact of Technology

Schedule: 11:00 a.m. EST / 4:00 p.m. BST

Technology continues to impact the relationship between businesses and their stakeholders, with data exchange, digital service provision and innovation all driving discussion. Our panel of experts will address data-driven approaches to patient care, the impact of technology on regulation, and IP, data privacy and cyber security issues in the healthcare and life sciences industry.

Key Insights

• Using technology to analyze data and provide better patient care
• The impact of regulation on the modernization of compliance programs
• Safeguarding IP with privacy, cyber and IT procedures
• Balancing data privacy, cyber and the efficient exchange of patient data
• Protecting assets against cyber-attacks and unforced errors

Panelists

• Alpa Kamdar, Managing Director, Duff & Phelps
• Stacy Scott, Managing Director, Kroll
• Jan Bregman, Senior Manager, AtaCor Medical, Inc

Intellectual Property – Management, Protection and Enforcement

Schedule: 12:15 p.m. EST / 5:15 p.m. BST

Join our panel of leading attorneys for a discussion focused on current issues facing the life sciences industry with respect to the management, protection and enforcement of IP rights in the UK, Europe and the U.S.

Key Insights

• Cross-border challenges
• The UK and Europe post Brexit
• The International Trade Commission
• The impact of biosimilars on the IP landscape

Panelists

• Pauline Booth, Managing Director, Duff & Phelps
• Barbara Fiacco, Partner, Foley Hoag
• Dr. Penny Gilbert, Partner, Powell Gilbert LLP, London
• PJ McCarthy, Partner, Goodwin

Day 3: Thursday, June 24

The Role of Regulation

Schedule: 11:00 a.m. EST / 4:00 p.m. BST

Chris Campbell, Chief Strategist at Kroll, Michael Kiely, President of U.S. Government Affairs at UPS and Jon Selib, Senior Vice President, Global Policy & Public Affairs at Pfizer, will sit down for a fireside chat on the impact of regulation on the life sciences industry. They will discuss global regulations and emerging hot topics.

Key Insights

• Will regulators be globally aligned
• ESG Regulation under the Biden Administration
• Is there potential for industry and regulators to work closely in sharing ‘real-time’ data
• Critical emerging trends and hot topics

Panelists

• Chris Campbell, Chief Strategist, Kroll
• Jon Selib, Senior Vice President, Global Policy & Public Affairs, Pfizer
• Michael Kiely, President of U.S. Government Affairs, UPS 

Navigating the Elevated Risk Environment

Schedule: 12:15 p.m. EST / 5:15 p.m. BST

The discussion will provide insights on how the post-COVID-19 environment is challenging with the pharmaceutical and medical device industries. The increased public scrutiny and rapid development of and changes to these industries over the past year amplifies existing operational risks. Our panel of experts will address evolving risks challenging life sciences global-supply chain, identifying risk exposure and navigating the complex regulatory landscape.

Key Insights

• Developing strategies that de-risk businesses and operating models
• Overview of various U.S. and a selection of other government policies and actions impacting the life science’s global supply chains, including for example, price gouging rules 
• Anticipating and addressing increased costs of compliance
• Strengthening procedures around risk management

Panelists

• Roeland Van Aelst, EMEA Lead Third Party Intermediary Ethics & Compliance, Johnson & Johnson
• John Ingrassia, Senior Counsel, Proskauer Rose LLP
• Tasneem Azad, Managing Director, Duff & Phelps, a Kroll Business
• Daniel Hartnett, Associate Managing Director, Kroll